XML 58 R35.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Joint Ventures and Other Equity Method Affiliates (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2017
Equity Method Investments and Joint Ventures [Abstract] |
Schedule of Fair Value of Assets Acquired and Liabilities Assumed | The estimated fair value of assets acquired and liabilities assumed from Cubist is as follows:
Estimated fair value at January 21, 2015 |
Cash and cash equivalents | $ | 733 |
Accounts receivable | 123 |
Inventories | 216 |
Other current assets | 55 |
Property, plant and equipment | 151 |
Identifiable intangible assets: |
Products and product rights (11 year weighted-average useful life) | 6,923 |
IPR&D | 50 |
Other noncurrent assets | 184 |
Current liabilities (1) | (233 | )
Deferred income tax liabilities | (2,519 | )
Long-term debt | (1,900 | )
Other noncurrent liabilities (1) | (122 | )
Total identifiable net assets | 3,661 |
Goodwill (2) | 4,670 |
Consideration transferred | $ | 8,331 |
(1) | Included in current liabilities and other noncurrent liabilities is contingent consideration of $73 million and $50 million, respectively.
(2) | The goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Pharmaceutical segment. The goodwill is not deductible for tax purposes.
The net impact of the termination of the SPMSD joint venture is as follows:
Products and product rights (8 year useful life) | $ | 936 |
Accounts receivable | 133 |
Income taxes payable | (221 | )
Deferred income tax liabilities | (147 | )
Other, net | 47 |
Net assets acquired | 748 |
Consideration payable to Sanofi, net | (392 | )
Derecognition of Merck’s previously held equity investment in SPMSD | (183 | )
Increase in net assets | 173 |
Merck’s share of restructuring costs related to the termination | (77 | )
Net gain on termination of SPMSD joint venture (1) | $ | 96 |
(1) Recorded in Other (income) expense, net.

X
- References No definition available. + Details
Name: | us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472 + Details
Name: | us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration